Intraocular Inflammation with faricimab: insights from Manufacturer and User Facility Device Experience (MAUDE) database
<p dir="ltr">Since its introduction in 2019, brolucizumab’s safety has been called into question due to numerous reports of IOI following intravitreal injections. In 2020, post-marketing data showed that there was a confirmed safety alarm of severe ocular adverse events such as retin...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Published: |
2024
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|